

CERTIFICATE

Survey of 21 May 2021

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 13 - LMW Heparin (281):

Validity 12 months:

Low mol. weight Heparin

Haemostasis 22 - Dabigatran (502):

Validity 12 months:

Dabigatran

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

Haemostasis 25 - Apixaban (504):


Validity 12 months:

Apixaban


(R) analysis is subject to the RiliBÄK

Participant:
2430
MUDr., PhD. Martin Spacek
Vseobecna fakultni nemocnice v Praze
Centralni hematologicke laboratore ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 29 June 2021



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)